Hongchun Liu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3544849/publications.pdf

Version: 2024-02-01

623734 610901 27 618 14 24 citations g-index h-index papers 28 28 28 1147 times ranked docs citations citing authors all docs

#	Article	IF	CITATIONS
1	Adjusted degradation of BRD4 S and BRD4 L based on fine structural modifications of the pyrrolopyridone scaffold. European Journal of Medicinal Chemistry, 2022, 236, 114259.	5.5	8
2	Development of hedgehog pathway inhibitors by epigenetically targeting GLI through BET bromodomain for the treatment of medulloblastoma. Acta Pharmaceutica Sinica B, 2021, 11, 488-504.	12.0	16
3	Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes. European Journal of Medicinal Chemistry, 2021, 209, 112868.	5 . 5	32
4	Clerodenoids Aâ€"F: Câ€ring Aromatized and/or Rearranged Abietane Diterpenoids from <i>Clerodendrum chinense</i> var. <i>simplex</i> Chinese Journal of Chemistry, 2021, 39, 1891-1897.	4.9	16
5	Synthesis of the analogs of plocabulin and their preliminary structure-activity relationship study. Bioorganic and Medicinal Chemistry Letters, 2021, 51, 128355.	2.2	1
6	Inhibition of Tumor Lymphangiogenesis is an Important Part that EGFR-TKIs Play in the Treatment of NSCLC. Journal of Cancer, 2020, 11, 241-250.	2.5	13
7	Optimized HSP90 mediated fluorescent probes for cancer-specific bioimaging. Journal of Materials Chemistry B, 2020, 8, 1878-1896.	5.8	5
8	Synthesis and biological activity of C-7, C-9 and C-10 modified taxane analogues from 1-deoxybaccatin VI. Bioorganic and Medicinal Chemistry, 2020, 28, 115736.	3.0	1
9	Cytotoxic Germacrane-Type Sesquiterpene Lactones from the Whole Plant of <i>Carpesium lipskyi</i> Journal of Natural Products, 2019, 82, 919-927.	3.0	16
10	Identification and Therapeutic Intervention of Coactivated Anaplastic Lymphoma Kinase, Fibroblast Growth Factor Receptor 2, and Ephrin Typeâ€A Receptor 5 Kinases in Hepatocellular Carcinoma. Hepatology, 2019, 69, 573-586.	7.3	12
11	Design, synthesis and pharmacological evaluation of ALK and Hsp90 dual inhibitors bearing resorcinol and 2,4-diaminopyrimidine motifs. European Journal of Medicinal Chemistry, 2018, 152, 76-86.	5.5	23
12	A tightly controlled Src-YAP signaling axis determines therapeutic response to dasatinib in renal cell carcinoma. Theranostics, 2018, 8, 3256-3267.	10.0	38
13	Isolation and Structure Characterization of Cytotoxic Phorbol Esters from the Seeds of Croton tiglium. Planta Medica, 2017, 83, 1361-1367.	1.3	17
14	Synthesis and structure–activity relationship study of pyrazolo[3,4- d]pyrimidines as tyrosine kinase RET inhibitors. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 2544-2548.	2.2	24
15	Design, Synthesis, and Biological Evaluation of the First c-Met/HDAC Inhibitors Based on Pyridazinone Derivatives. ACS Medicinal Chemistry Letters, 2017, 8, 830-834.	2.8	40
16	Aspirin disrupts the mTOR-Raptor complex and potentiates the anti-cancer activities of sorafenib via mTORC1 inhibition. Cancer Letters, 2017, 406, 105-115.	7.2	32
17	Design, synthesis and pharmacological evaluation of 4,5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors. European Journal of Medicinal Chemistry, 2017, 125, 315-326.	5.5	32
18	Discovery and Biological Evaluation of a Series of Pyrrolo [2,3-b] pyrazines as Novel FGFR Inhibitors. Molecules, 2017, 22, 583.	3.8	8

Hongchun Liu

#	Article	IF	CITATIONS
19	Development of Heat Shock Protein (Hsp90) Inhibitors To Combat Resistance to Tyrosine Kinase Inhibitors through Hsp90–Kinase Interactions. Journal of Medicinal Chemistry, 2016, 59, 5563-5586.	6.4	53
20	Tetrahydroisoquinolines as novel histone deacetylase inhibitors for treatment of cancer. Acta Pharmaceutica Sinica B, 2016, 6, 93-99.	12.0	18
21	Modified Release and Improved Stability of Unstable BCS II Drug by Using Cyclodextrin Complex as Carrier To Remotely Load Drug into Niosomes. Molecular Pharmaceutics, 2016, 13, 113-124.	4.6	9
22	Featured Article: Teriflunomide, an immunomodulatory drug, exerts anticancer activity in triple negative breast cancer cells. Experimental Biology and Medicine, 2015, 240, 426-437.	2.4	42
23	FS-93, an Hsp90 inhibitor, induces G2/M arrest and apoptosis via the degradation of client proteins in oncogene addicted and derived resistant cancer cells. Oncoscience, 2015, 2, 419-427.	2.2	6
24	A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cells. Oncology Reports, 2014, 32, 627-634.	2.6	6
25	Discovery of potent N-(isoxazol-5-yl)amides as HSP90 inhibitors. European Journal of Medicinal Chemistry, 2014, 87, 765-781.	5.5	33
26	A novel long non-coding RNA-ARA: Adriamycin Resistance Associated. Biochemical Pharmacology, 2014, 87, 254-283.	4.4	100
27	Identification of a new series of potent diphenol HSP90 inhibitors by fragment merging and structure-based optimization. Bioorganic and Medicinal Chemistry Letters, 2014, 24, 2525-2529.	2.2	16